BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36550819)

  • 1. The cGAS-STING pathway-related gene signature can predict patient prognosis and immunotherapy responses in prostate adenocarcinoma.
    Zhuo X; Dai H; Yu S
    Medicine (Baltimore); 2022 Dec; 101(50):e31290. PubMed ID: 36550819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
    Yang KS; Xu CQ; Lv J
    Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    He XU; Yu Y; Zhang X; Gao C; Wang H; Liu C
    Cancer Genomics Proteomics; 2023; 20(5):476-486. PubMed ID: 37643778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Cytosolic DNA Sensor cGAS-STING as Immune-Related Risk Factor in Renal Carcinoma following Pan-Cancer Analysis.
    Wu Z; Lin Y; Liu LM; Hou YL; Qin WT; Zhang L; Jiang SH; Yang Q; Bai YR
    J Immunol Res; 2022; 2022():7978042. PubMed ID: 35983076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
    Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
    Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
    Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
    Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A N
    Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
    J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma.
    Qi Z; Yan F; Chen D; Xing W; Li Q; Zeng W; Bi B; Xie J
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33006365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets.
    Jiang F; Lin H; Yan H; Sun X; Yang J; Dong M
    Eur J Med Res; 2022 Oct; 27(1):205. PubMed ID: 36253873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
    Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
    Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway.
    Li M; Bai G; Cen Y; Xie Q; Chen J; Chen J; Chen Q; Zhong W; Zhou X
    J Transl Med; 2023 Dec; 21(1):884. PubMed ID: 38057852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
    Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes.
    Chen C; Wang J; Dong C; Lim D; Feng Z
    Front Genet; 2023; 14():1121018. PubMed ID: 37051596
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular map of cGAS-STING pathway-related genes in bladder cancer: the perspective toward immune microenvironment and prognosis.
    Wei D; Liu Y; Yuan Y; Li Y; Zhao F; Qin X
    Aging (Albany NY); 2024 Jan; 16(2):1516-1535. PubMed ID: 38240703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma.
    Zhu C; Li J; Yao M; Fang C
    BMC Oral Health; 2021 Oct; 21(1):506. PubMed ID: 34625078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 18. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
    Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
    Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.
    Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL
    Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.